Antitumor effect of murine dendritic and tumor cells transduced with IL-2 gene

Folia Histochemica et Cytobiologica

Volumn 50, Issue 3, 2012, Pages 414-419

  Wojas Turek, Justyna ^a   Pajtasz Piasecka, Elzbieta ^a   Rossowska, Joanna ^a   Piasecki, Egbert ^a   Duś, Danuta ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Dendritic or tumor cell vaccine; IL 2 gene transduction; MC38 murine colon carcinoma

Indexed keywords

INTERLEUKIN 2; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE; IN VITRO STUDY; IN VIVO STUDY; INTERLEUKIN 2 GENE; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

EID: 84867772583     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0056     Document Type: Article

References (12)

1. Escobar A, López M, Serrano A et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005;142:555-568.
2. Ojima T, Iwahashi M, Nakamura M et al. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int J Oncol. 2005;28:947-953.
3. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008; 19;29:372-383.
4. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev. 2008;226:19-28.
5. Devita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 2005.
6. Kusnierczyk H, Pajtasz-Piasecka E, Koten JW, Bijleveld C, Krawczyk K, Den Otter W. Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother. 2004;53:445-452.
7. Podhajcer OL, Lopez MV, Mazzolini G. Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev. 2007;18:183-194.
8. Pajtasz-Piasecka E, Kuśnierczyk H, Salwa J, Konarski L, Radzikowski C. Growth inhibition of transplantable tumors in mice by mIL-2-secreting murine plasmocytoma cells used alone or in combination with a cytostatic agent. Arch Immunol Ther Exp. 1995;43:281-292.
9. Pajtasz-Piasecka E, Szyda A, Rossowska J et al. Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha). 2004;50:7-14.
10. Rossowska J, Pajtasz-Piasecka E, Ryśnik O et al. Generation of antitumor response by IL-2-transduced JAWS II dendritic cells. Immunobiology. 2011;216;10:1074-1084.
11. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;29; 313:1960-1964.
12. + T lymphocytes. Cancer Res. 2010; 1;70:8368-8377.